Literature DB >> 21630124

Outcomes of screening-detected ductal carcinoma in situ treated with wide excision alone.

Jonathan Fong1, Emil D Kurniawan, Allison K Rose, Arlene Mou, John P Collins, Julie A Miller, G Bruce Mann.   

Abstract

BACKGROUND: Ductal carcinoma in situ (DCIS) is commonly identified on screening mammography. Standard treatment for localized DCIS is wide local excision (WLE) and adjuvant radiotherapy. This approach represents overtreatment in many cases, where the DCIS would never have become clinically significant, or where less intensive treatment would have been satisfactory. We reviewed the medium-term outcome of a cohort of screen detected DCIS patients treated mainly with WLE without radiotherapy.
METHODS: All patients diagnosed with DCIS at NorthWestern BreastScreen between January 1994 and December 2005 were identified from a prospective database. Demographic, pathological, treatment, and outcome data were collected and analyzed. Survival and local recurrence (LR) rates were determined, and associations between various factors and recurrence were analyzed.
RESULTS: A total of 422 patients were diagnosed with DCIS. There were 400 patients treated with WLE, and 27 of these received adjuvant radiotherapy. The 5- and 8-year overall and breast cancer specific survival rates were 96.1 and 91.3%, and 99.6 and 99.3%, respectively. The local recurrence rate was 15.4 and 17.1% at 5 and 8 years. Of 56 local recurrences, 34 had WLE after recurrence, 16 of which had adjuvant radiotherapy. No single factor was statistically significantly associated with local recurrence, although combining factors revealed groups where the LR rate was less than 5%.
CONCLUSIONS: Breast cancer specific mortality was very low in this cohort of older patients with screen-detected DCIS. There was a moderate rate of local recurrence that could usually be salvaged with breast conservation. Decisions regarding adjuvant radiotherapy should take these findings into account.

Entities:  

Mesh:

Year:  2011        PMID: 21630124     DOI: 10.1245/s10434-011-1748-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop.

Authors:  Ann H Partridge; Joann G Elmore; Debbie Saslow; Worta McCaskill-Stevens; Stuart J Schnitt
Journal:  CA Cancer J Clin       Date:  2012-04-04       Impact factor: 508.702

2.  Copy number analysis of ductal carcinoma in situ with and without recurrence.

Authors:  Kylie L Gorringe; Sally M Hunter; Jia-Min Pang; Ken Opeskin; Prue Hill; Simone M Rowley; David Y H Choong; Ella R Thompson; Alexander Dobrovic; Stephen B Fox; G Bruce Mann; Ian G Campbell
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

3.  Modeling the effectiveness of initial management strategies for ductal carcinoma in situ.

Authors:  Djøra I Soeteman; Natasha K Stout; Elissa M Ozanne; Caprice Greenberg; Michael J Hassett; Deborah Schrag; Rinaa S Punglia
Journal:  J Natl Cancer Inst       Date:  2013-05-03       Impact factor: 13.506

4.  Ductal carcinoma in situ: what can we learn from clinical trials?

Authors:  Lucio Fortunato; Igor Poccia; Ugo de Paula; Elena Santini
Journal:  Int J Surg Oncol       Date:  2012-05-09

Review 5.  Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

Authors:  Kylie L Gorringe; Stephen B Fox
Journal:  Front Oncol       Date:  2017-10-23       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.